Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Pipeline & R&D

NeOnc shares early glioma data for nasal NEO100; neither pipeline drug is approved

The Nasdaq-listed company's slide deck puts a small, uncontrolled 24-patient study at the centre of its brain-tumour pitch, with no regulatory milestone or deal terms attached.

18 Nov 2026 · Neonc Technologies Holdings, Inc. NTHI · Company news

NeOnc Technologies (NASDAQ: NTHI) has put early clinical results for its intranasal brain-cancer candidate NEO100 at the front of a slide deck dated 18 November 2026. The document also covers NEO212, an oral drug. The deck gives no revenue, partnership or financing details, so the commercial case rests on the clinical data alone.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Neonc Technologies Holdings, Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Pipeline & R&DAll →